A detailed history of Nisa Investment Advisors, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 2,328 shares of RXRX stock, worth $16,854. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,328
Previous 2,025 14.96%
Holding current value
$16,854
Previous $15,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$5.92 - $8.6 $1,793 - $2,605
303 Added 14.96%
2,328 $15,000
Q2 2024

Jul 19, 2024

BUY
$7.35 - $10.05 $5,497 - $7,517
748 Added 58.57%
2,025 $15,000
Q1 2024

May 01, 2024

BUY
$9.13 - $15.52 $1,113 - $1,893
122 Added 10.56%
1,277 $12,000
Q4 2023

Jan 25, 2024

SELL
$5.09 - $10.79 $14,582 - $30,913
-2,865 Reduced 71.27%
1,155 $11,000
Q3 2023

Nov 02, 2023

SELL
$6.59 - $15.86 $131 - $317
-20 Reduced 0.5%
4,020 $30,000
Q2 2023

Aug 11, 2023

SELL
$4.56 - $9.94 $211,173 - $460,321
-46,310 Reduced 91.98%
4,040 $30,000
Q1 2023

May 02, 2023

BUY
$6.42 - $9.64 $128 - $192
20 Added 0.04%
50,350 $336,000
Q4 2022

Feb 02, 2023

SELL
$7.16 - $12.7 $386 - $685
-54 Reduced 0.11%
50,330 $388,000
Q3 2022

Nov 07, 2022

SELL
$7.83 - $13.6 $211,378 - $367,145
-26,996 Reduced 34.89%
50,384 $536,000
Q2 2022

Aug 03, 2022

BUY
$5.04 - $9.26 $384,552 - $706,538
76,300 Added 7064.81%
77,380 $630,000
Q1 2022

Apr 29, 2022

BUY
$6.16 - $18.03 $6,652 - $19,472
1,080 New
1,080 $8,000
Q4 2021

Feb 03, 2022

SELL
$16.14 - $21.86 $44,820 - $60,705
-2,777 Closed
0 $0
Q3 2021

Oct 18, 2021

BUY
$19.03 - $41.33 $52,846 - $114,773
2,777 New
2,777 $64,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.31B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.